Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
1 - 10of about 643 News
1 - 10of about 643 News
October 27, 2021
Not intended for U.S. and UK Media – The American Society of Nephrology (ASN)’s Kidney Week 2021:
Bayer to present new data from comprehensive finerenone clinical trial program
READ MORE
October 19, 2021
Bayer fuels leading market positions in Crop Science through delivery of unmatched innovation
READ MORE
September 20, 2021
Not intended for U.S. and UK Media
Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease
READ MORE
September 16, 2021
Not intended for U.S. and UK Media – ESMO Congress 2021:
Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerability profile for both adult and pediatric patients with TRK fusion cancer
READ MORE
September 09, 2021
Not intended for U.S. and UK Media
Bayer to highlight expanded research from growing oncology portfolio at ESMO Congress 2021
READ MORE
September 06, 2021
Not intended for U.S. and UK Media
Bayer’s Eliapixant significantly decreased cough frequency in Phase IIb trial in patients with refractory chronic cough
READ MORE
August 31, 2021
Not intended for U.S. and UK Media
Bayer starts Phase III clinical development program OASIS with Elinzanetant
READ MORE
August 28, 2021
Not intended for U.S. and UK Media – Data from Phase III study FIGARO-DKD and from FIDELITY, a prespecified meta-analysis of FIGARO-DKD and FIDELIO-DKD, presented at ESC Congress 2021
New Data on Finerenone for the protection of patients with chronic kidney disease and type 2 diabetes from cardiovascular events and kidney disease progression
READ MORE
August 17, 2021
Not intended for U.S. and UK Media – ESC Congress 2021 – The Digital Experience:
Bayer to present data from cardiovascular portfolio, including late breaking data from Phase III FIGARO-DKD (finerenone) and various Xarelto™ studies
READ MORE
August 16, 2021
Bayer announces filing of petition to U.S. Supreme Court for review of Hardeman decision
READ MORE
1 - 10of about 643 News
1 - 10of about 643 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases

read more